Intech Investment Management LLC Has $1.49 Million Stock Position in Haemonetics Corporation $HAE

Intech Investment Management LLC reduced its stake in shares of Haemonetics Corporation (NYSE:HAE) by 32.4% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 18,589 shares of the medical instruments supplier’s stock after selling 8,900 shares during the quarter. Intech Investment Management LLC’s holdings in Haemonetics were worth $1,490,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the business. Hantz Financial Services Inc. lifted its position in shares of Haemonetics by 52.5% during the 4th quarter. Hantz Financial Services Inc. now owns 1,714 shares of the medical instruments supplier’s stock worth $137,000 after buying an additional 590 shares during the last quarter. EverSource Wealth Advisors LLC lifted its position in shares of Haemonetics by 366.9% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,709 shares of the medical instruments supplier’s stock worth $137,000 after buying an additional 1,343 shares during the last quarter. Legato Capital Management LLC bought a new stake in shares of Haemonetics during the 4th quarter worth $1,057,000. Global Retirement Partners LLC bought a new stake in shares of Haemonetics during the 4th quarter worth $270,000. Finally, Leonteq Securities AG bought a new stake in shares of Haemonetics during the 4th quarter worth $30,000. 99.67% of the stock is currently owned by institutional investors.

Haemonetics Price Performance

Haemonetics stock opened at $71.31 on Friday. The company has a current ratio of 2.95, a quick ratio of 1.87 and a debt-to-equity ratio of 1.53. The company has a market capitalization of $3.24 billion, a PE ratio of 35.30, a P/E/G ratio of 1.41 and a beta of 0.56. Haemonetics Corporation has a 12 month low of $47.31 and a 12 month high of $87.32. The stock has a 50-day moving average price of $60.00 and a two-hundred day moving average price of $67.27.

Haemonetics (NYSE:HAE) last posted its earnings results on Thursday, May 7th. The medical instruments supplier reported $1.29 EPS for the quarter, beating the consensus estimate of $1.28 by $0.01. The firm had revenue of $346.35 million during the quarter, compared to the consensus estimate of $336.83 million. Haemonetics had a return on equity of 27.30% and a net margin of 7.29%.The business’s quarterly revenue was up 4.8% on a year-over-year basis. During the same period last year, the company earned $1.24 earnings per share. Haemonetics has set its FY 2027 guidance at 5.258-5.307 EPS. Analysts expect that Haemonetics Corporation will post 5.23 EPS for the current year.

Analysts Set New Price Targets

Several analysts recently weighed in on HAE shares. Barrington Research dropped their price objective on Haemonetics from $94.00 to $89.00 and set an “outperform” rating for the company in a research report on Tuesday, May 12th. Citigroup upped their price objective on Haemonetics from $64.00 to $70.00 and gave the stock a “neutral” rating in a research report on Thursday, May 28th. Weiss Ratings downgraded Haemonetics from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Thursday, May 21st. Mizuho dropped their price objective on Haemonetics from $80.00 to $70.00 and set an “outperform” rating for the company in a research report on Monday, April 13th. Finally, JPMorgan Chase & Co. dropped their price objective on Haemonetics from $74.00 to $62.00 and set a “neutral” rating for the company in a research report on Friday, May 8th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $77.11.

Haemonetics Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.